Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (381-390 of 440) with videos related to

Pageof 44
Sort By:
Cancer Discovery|March 14, 2019
Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in CancerDong Chen, Siyuan Xia, Mei Wang, et al.
The New England Journal of Medicine|February 24, 2021
Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaNikhil C Munshi, Larry D Anderson, Nina Shah, et al.
Nature Communications|May 9, 2013
Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformationTaro Hitosugi, Lu Zhou, Jun Fan, et al.
Blood Cancer Journal|September 5, 2020
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 studyMeletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
Blood|January 17, 2014
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myelomaPaul G Richardson, Wanling Xie, Sundar Jagannath, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 18, 2013
Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myelomaAyman Saad, Anuj Mahindra, Mei-Jie Zhang, et al.
Cancer Cell|July 24, 2018
MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK ActivationLingtao Jin, Jaemoo Chun, Chaoyun Pan, et al.
Blood|April 14, 2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myelomaPaul G Richardson, Edie Weller, Sagar Lonial, et al.
Molecular Cell|February 4, 2014
Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complexJun Fan, Changliang Shan, Hee-Bum Kang, et al.
Blood|December 17, 2013
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapyGeorge Mulligan, David I Lichter, Alessandra Di Bacco, et al.
Pageof 44

Showing results (381-390 of 440) with videos related to

Sort By:
Pageof 44
Cancer Discovery|March 14, 2019
Mutant and Wild-Type Isocitrate Dehydrogenase 1 Share Enhancing Mechanisms Involving Distinct Tyrosine Kinase Cascades in CancerDong Chen, Siyuan Xia, Mei Wang, et al.
The New England Journal of Medicine|February 24, 2021
Idecabtagene Vicleucel in Relapsed and Refractory Multiple MyelomaNikhil C Munshi, Larry D Anderson, Nina Shah, et al.
Nature Communications|May 9, 2013
Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformationTaro Hitosugi, Lu Zhou, Jun Fan, et al.
Blood Cancer Journal|September 5, 2020
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 studyMeletios A Dimopoulos, Sagar Lonial, Darrell White, et al.
Blood|January 17, 2014
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myelomaPaul G Richardson, Wanling Xie, Sundar Jagannath, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 18, 2013
Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myelomaAyman Saad, Anuj Mahindra, Mei-Jie Zhang, et al.
Cancer Cell|July 24, 2018
MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK ActivationLingtao Jin, Jaemoo Chun, Chaoyun Pan, et al.
Blood|April 14, 2010
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myelomaPaul G Richardson, Edie Weller, Sagar Lonial, et al.
Molecular Cell|February 4, 2014
Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complexJun Fan, Changliang Shan, Hee-Bum Kang, et al.
Blood|December 17, 2013
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapyGeorge Mulligan, David I Lichter, Alessandra Di Bacco, et al.
Pageof 44